StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Rhythm Pharmaceuticals (RYTM) PT Lowered to $152 at Citizens on 'Disappointing' Phase 3 EMANATE Trial
March 17, 2026 5:22 AM
Citizens analyst Jonathan Wolleben lowered the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $152.00 (from $176.00) while maintaining a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst PT Change
